Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year target prices for Kiniksa Pharmaceuticals' stock. Their KNSA share price forecasts range from $20.00 to $20.00. On average, they anticipate the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 76.1% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.

Kiniksa Pharmaceuticals' stock was trading at $14.98 at the beginning of 2023. Since then, KNSA stock has decreased by 24.2% and is now trading at $11.36.
View the best growth stocks for 2023 here.

Kiniksa Pharmaceuticals saw a decrease in short interest in March. As of March 15th, there was short interest totaling 2,520,000 shares, a decrease of 7.4% from the February 28th total of 2,720,000 shares. Based on an average trading volume of 374,600 shares, the short-interest ratio is currently 6.7 days.
View Kiniksa Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our KNSA earnings forecast.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its earnings results on Monday, November, 1st. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.21. The firm earned $12.10 million during the quarter, compared to analysts' expectations of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 83.28% and a trailing twelve-month return on equity of 2.18%.

ETFs with the largest weight of Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco DWA Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS), SPDR S&P Biotech ETF (XBI), Hartford Multifactor Small Cap ETF (ROSC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB).

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.11%), ArrowMark Colorado Holdings LLC (1.03%), Rice Hall James & Associates LLC (1.00%), Morgan Stanley (0.87%), Geode Capital Management LLC (0.78%) and Granahan Investment Management LLC (0.73%). Insiders that own company stock include Barry D Quart, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends.

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KNSA stock can currently be purchased for approximately $11.36.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $792.36 million and generates $220.18 million in revenue each year. The company earns $183.36 million in net income (profit) each year or $2.59 on an earnings per share basis.

The company employs 215 workers across the globe.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com.